HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper
S Fidler, S Lewin, S Deeks, OS Sogaard, L Vandekerckhove, S Collins, D Kelly, J Singh, M Caskey, J Frater
JOURNAL OF VIRUS ERADICATION | MEDISCRIPT LTD | Published : 2021
This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next 12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI in the context of circulating SARS-CoV-2.
This article is a discussion document and therefore represents the views of the co-authors, there is no specific funding associated with this work. JF and SF acknowledge funding from Oxford and Imperial College NIHR BRC which suport their salaries through their university.